Sector News

Danone, Nestle, KKR and more suit up for GSK consumer bidding war: report

May 25, 2018
Life sciences

GlaxoSmithKline’s Indian consumer health sale may just touch off a bidding war.

Major players including Danone, Hindustan Unilever and Nestlé are squaring off against private equity firm KKR to nab Glaxo’s 72.5% stake in its Indian consumer products business, The Economic Times reported. PepsiCo, Abbott and Mondelez are reportedly in the mix, too.

The sale could drum up $4 billion, the India-based Times says, which could make it the biggest deal in consumer history there. And a major cash infusion is exactly what GlaxoSmithKline is looking for to help fund its own consumer buy: A $13 billion pickup of Novartis’ share in their consumer joint venture, agreed upon in March.

For some of the rumored bidders in India, such as Danone and Abbott, the Indian company—which markets well-known drink brands Horlicks and Boost—would fit right into their portfolios. KKR, though, could be a tough M&A rival: It’s one of the most aggressive PE investors in India, TET noted, and it’s been scouting for big-time assets in the country.

For now, talks are still in the early stages, the Times’ sources said. The process should pick up steam next month, after initial bids become formal, nonbinding offers and GSK pares down its list of suitors to continue negotiations.

GSK said it was weighing a sale of its share in GlaxoSmithKline Consumer Healthcare Ltd., which is a public company listed on India’s stock exchanges, at the same time it went public with the Novartis deal agreement. But as Glaxo was quick to point out, it’s still focused squarely on the Indian market with its other products.

India “remains a priority market for GSK investment and growth,” the pharma giant said at the time, adding that it would continue to back OTC and oral health brands in the country and invest in pharmaceuticals and vaccines there, too.

By Carly Helfand

Source: Fierce Pharma

comments closed

Related News

May 27, 2023

Positive opinion for Novo Nordisk’s Sogroya

Life sciences

Novo Nordisk has announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has provided a positive opinion for the company’s Sogroya therapy. The once-weekly treatment – also known as somapacitan – is for the replacement of endogenous growth hormone (GH) in aged children three years and older.

May 27, 2023

Medtronic acquires insulin patch pump maker EOFlow for $738M amid new MiniMed rollout

Life sciences

Medtronic is set to acquire EOFlow, the South Korea-based maker of an insulin patch pump. In its announcement of the deal Thursday, Medtronic suggested that integrating the tubeless device with its own continuous glucose monitors and meal-detection algorithm could create a new closed-loop system for largely hands-off diabetes management.

May 27, 2023

Apnimed cracks sleep apnea puzzle, hits primary goal in phase 2 study

Life sciences

Apnimed started the year by bagging nearly $80 million in extended series C funds and the momentum has kept up, with the sleep-apnea-focused biotech nailing its goals in a phase 2 study. “For those who cannot tolerate current treatments, AD109 has the potential to be a convenient, oral pill that could improve people’s quality of life both at night and during the day.”

How can we help you?

We're easy to reach